<!-- wp:image {"id":594,"align":"right","width":496,"height":367} -->
<div class="wp-block-image"><figure class="alignright is-resized"><img src="https://sidikkanali.az/wp-content/uploads/2019/11/screen_shot_2019-11-25_at_11.png" alt="" class="wp-image-594" width="496" height="367"/><figcaption> Creavo Medical Technologies has announced the start of its 510-patient study, evaluating the role of magnetocardiography for predicting ventricular arrhythmias in patients who have been identified at risk of sudden cardiac death. </figcaption></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>The UK medical device company has initiated the joint study with University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, and will start performing MCG scans – which generate a magnetic field map of the heart.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The company confirmed that the tests will be run on patients who fulfil National Institute for Health and Care Excellence (NICE) guidelines for receiving an implantable cardioverter-defibrillator (ICD).</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Following the MCG scan, patients will then be assessed using the standard ICD follow-up procedure, set to take place over a 21-month period in order to record which patients ultimately received therapies from their ICD.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Currently, the majority of ICDs are implanted in patients who have suffered a myocardial infarction and are known to have a weakened heart, but research suggests “only around 10-15% of ICD recipients subsequently suffer a ventricular arrhythmia and receive a treatment from their ICD” explained Dr Tom Lachlan, research fellow in Cardiology at UHCW.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>He continued, “This means that a significant number of patients deemed ‘at risk’ are implanted with ICDs which are never needed, and this can be severely detrimental to their overall health as well as being a costly undertaking for health services.”</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Due to the current predicament, Dr Lachlan says that he is “excited by the potential of this study to more accurately predict which patients will develop a ventricular arrhythmia that requires therapy from the ICD, and therefore improve health outcomes for those at risk of SCD and enable health services to more efficiently allocate their resources.”</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The company and University hope that correlations can be identified to further risk-stratify patients within a pool determined to be at risk of SCD under current guidelines, to enable physicians to prescribe defibrillators more accurately.</p>
<!-- /wp:paragraph -->